# A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Source: https://onco.cc/trials/nct06439771/  
OnCo record `nct06439771` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of YL202 should be intravenously infused in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC is a phase 2 interventional study registered as NCT06439771 by MediLink Therapeutics (Suzhou) Co., Ltd., with 180 participants planned, started 2024-04-23 and due to reach its primary completion in 2026-07-30. Interventions recorded: YL202 should be intravenously infused.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06439771
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With Locally Advanced or Metastatic Breast Cancer With TNBC, HR-Positive, HER2-Zero-expression or HER2-Low-expression
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06439771: https://clinicaltrials.gov/study/NCT06439771

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06439771.json